More Stories

Informist, Friday, Jul. 31, 2026

 

Please click here to read all liners published on this story

--Sun Pharma Apr-Jun consol net profit INR 28.95 bln
--Analysts saw Sun Pharma Apr-Jun consol net profit at INR 30.11 bln
--Sun Pharma Apr-Jun consol revenue INR 153 bln
--Analysts saw Sun Pharma Apr-Jun consol revenue at INR 155.25 bln
--Sun Pharma Apr-Jun consol net profit INR 28.95 bln vs INR 22.79 bln yr ago
--Sun Pharma Apr-Jun consol revenue INR 153.00 bln vs INR 138.51 bln yr ago
--Sun Pharma Apr-Jun net profit includes one-time cost INR 2.04 bln
--Sun Pharma Apr-Jun consol EBITDA INR 44.18 bln, up 2.7% on year
--Sun Pharma Apr-Jun consol EBITDA margin 28.9% vs 31.1% year ago
--Sun Pharma Q1 India formulation sales INR 54.75 bln vs INR 47.21 bln yr ago
--Sun Pharma Apr-Jun US formulation sales $427 mln, down 9.7% on year
--Sun Pharma Apr-Jun US formulation sales 26.6% of total sales
--Sun Pharma Apr-Jun consol R&D spend INR 8.26 bln, 5.4% of sales
--Sun Pharma Q1 emerging mkt formulation sales $311 mln, up 4.2% on yr
--Sun Pharma Q1 Rest of World formulation sales $218 mln vs $219 mln yr ago
--Sun Pharma Apr-Jun API external sales INR 5.97 bln, up 10.5% on year
--Sun Pharma shrs fall to INR 1,973.10, down 1.4% vs up 2?rlier
--Sun Pharma shrs down; co misses Apr-Jun net profit, revenue expectations
--Sun Pharma: India formulation market share 8.5%, up 30 bps on year
--Sun Pharma: Q1 US revenue down YoY on decline in lenalidomide sales
--Sun Pharma: Ilumya, Cequa, Odomzo helped limit sales fall in Q1 from US
--Sun Pharma: Organon acquisition likely to complete by Jan-Mar

 

 

By Narayana Krishna

 

HYDERABAD – Sun Pharmaceutical Industries Ltd. reported a consolidated net profit of INR 28.95 billion for the June quarter, up over 27% on year. Its revenue from operations rose 10.5% on year to nearly INR 153 billion. While the company's bottom line rose at its fastest pace in seven quarters, it was still below analysts' expectations. The performance in the June quarter was mainly affected by the absence of sales of generic cancer drug Revlimid in the US.
 

Analysts had estimated Sun Pharma's June quarter consolidated net profit at INR 30.11 billion on a revenue of INR 155.25 billion. On a sequential basis, the company's net profit rose nearly 7% and its revenue grew 5%.  

 

The company incurred an exceptional cost north of INR 2 billion for the June quarter. It spent INR 1.67 billion on acquisition-related and transaction costs in relation to the definitive agreement to fully acquire Organon & Co. The remaining amount was spent on implementing the new labour codes. The company said Organon's shareholders have approved the proposed acquisition by the company, which is on track to close in early 2027.

Sun Pharma's June quarter US formulations sales declined by 9.7% on year to $427 million because of the absence of Revlimid sales. However, traction in its innovative medicine portfolio helped the company to offset the impact to some extent. Drugs such as Ilumya, Cequa, and Odomzo helped the company to offset a fall in sales in the US, the company said. The US is a key market for Sun Pharma and accounts for nearly 27% of its total sales.

 

Sales of the innovative medicines segment for the quarter rose 12.8% on year to $351 million. This segment accounts for nearly 22% of the company's total sales. The company's domestic formulation sales registered 16% year-on-year growth to INR 54.75 billion. "Our performance during the quarter was driven by strong momentum in India as well as innovative medicines, which delivered robust growth across the U.S. and international regions," Sun Pharma said. The market share in India formulations rose to 8.5%, improving 30 basis points on year, the company said.

 

The company said the recent semaglutide approvals in India, Brazil, and South Africa underscore its capabilities in developing complex peptide products for patients globally.

 

In its emerging markets formulations business, the company reported 4.2% year-on-year growth in sales to $331 million. The rest-of-the-world segment formulation sales were almost flat at $218 million. The company's active pharmaceutical ingredients business posted 10.5% year-on-year sales growth to INR 5.97 billion.

 

Sun Pharma said its research and development efforts continue to span both the innovative and generic businesses, with sustained investments aimed at strengthening its pipeline across key markets. The company spent INR 8.26 billion on R&D for the June quarter, 5.4% of its total sales.

 

The company's innovative pipeline currently includes five novel entities in the clinical stage. In the US, Sun Pharma has a broad generics portfolio with 558 approved abbreviated new drug applications, while 119 abbreviated new drug application filings, including 28 with tentative approvals, are awaiting clearance from the US Food and Drug Administration. During the June quarter, the company filed three abbreviated new drug applications and received approvals for six. Its portfolio also comprises 57 approved new drug applications, with 13 such applications pending approval.  More

 

For the June quarter, Sun Pharma's earnings before interest, tax, depreciation, and amortisation rose 2.7% on year to INR 44.18 billion, higher than the estimates. Analysts had estimated the EBITDA at INR 43.5 billion. The company's EBITDA margin for the quarter was 28.9% against 31.1% a year ago, while the estimates were in the range of 26–30%. The margin decline for the quarter was mainly on account of a high base from Revlimid sales in the year-ago quarter.

 

The company's total expenses for the quarter rose 13.5% on year to INR 117.21 billion. Other expenses were up 15.7% on year at INR 48.13 billion. The company also witnessed an over 14% year-on-year rise in raw material costs to INR 20.3 billion. Employee expenses rose 15% on year to INR 32.3 billion.

 

Friday, Sun Pharma shares ended at INR 1.990.50 on the National Stock Exchange, down 0.5% from Thursday. The company detailed its earnings during market hours. The stock had risen ahead of the earnings.  End

 

US$1 = INR 95.38

IST, or Indian Standard Time, is five-and-a-half hours ahead of GMT

 

Edited by Rajeev Pai

 

For users of real-time market data terminals, Informist news is available exclusively on the NSE Cogencis WorkStation.

 

Cogencis news is now Informist news. This follows the acquisition of Cogencis Information Services Ltd. by NSE Data & Analytics Ltd., a 100% subsidiary of the National Stock Exchange of India Ltd. As a part of the transaction, the news department of Cogencis has been sold to Informist Media Pvt. Ltd.

 

Informist Media Tel +91 (22) 6985-4000

Send comments to feedback@informistmedia.com

 

© Informist Media Pvt. Ltd. 2026. All rights reserved.